Cephalon Buys Rights to Mesoblast Stem Cell Therapies

Cephalon Inc. took a 20 percent stake in Mesoblast Ltd. and bought the rights to market the Australian company’s adult stem-cell therapies for heart and nervous system conditions in a deal potentially worth more than $2 billion.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.